Paper Details

  1. Home
  2. Paper Details

A phase I study of subcutaneous recombinant interleukin-2 in patients with advanced HIV disease while on zidovudine.

Author: ArmstrongJ A, GuptaP, HoM, HuangX L, McMahonD K, PazinG J, RinaldoC R, TripoliC, WhitesideT L

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Controlled Clinical TrialA clinical trial that evaluates the effectiveness of a treatment by comparing a group that receives the intervention with a group that receives a placebo or standard treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Subcutaneous rIL-2 was well-tolerated in patients with advanced HIV infection, with side effects similar to intravenous IL-2. It increased the number of eosinophils, CD4+ and CD8+ cells, and CD16+ cells, and boosted natural killer cell activity against uninfected and HIV-infected targets for up to 10 weeks.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: A Phase I study of subcutaneous recombinant interleukin-2 (rIL-2). DESIGN: Sixteen patients with advanced HIV infection receiving 600-1200 mg zidovudine per day were divided into three groups, which received sequentially 0.2 x 10(6), 0.7 x 10(6) or 2 x 10(6) units/m2 per day of rIL-2 sub...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/00002030-199401000-00009

データ提供：米国国立医学図書館（NLM）

Interleukin-2: A New Oasis in the Desert of HIV

HIV infection is a relentless desert, where the immune system weakens and becomes vulnerable to opportunistic infections. While antiretroviral therapies (ARTs) have revolutionized HIV treatment, the search for new approaches continues. This study investigates the potential of interleukin-2 (IL-2), a naturally occurring immune-boosting molecule, as an adjunct to ARTs, hoping to create a more robust and resilient immune system.

Interleukin-2: A Boost for the Immune System

The researchers conducted a Phase I study to evaluate the safety and efficacy of subcutaneous recombinant IL-2 in patients with advanced HIV disease who were already receiving zidovudine. They found that IL-2 was well-tolerated and had a positive impact on immune function, potentially boosting the body's ability to fight off infections. This is like finding a hidden spring in the desert of HIV, providing a source of strength to help the immune system regain its resilience.

Building a Stronger Oasis in the Desert of HIV

This study demonstrates the potential of IL-2 as an adjunct to ARTs in managing HIV. While further research is needed to fully understand its long-term effects and optimal dosage, it's a promising step towards developing new strategies for strengthening the immune system in those living with HIV. This is like building a stronger oasis in the desert of HIV, creating a more hospitable environment for the immune system to flourish and resist the harsh conditions of the disease.

Dr.Camel's Conclusion

The desert of HIV is a harsh and unforgiving environment, but IL-2 offers a potential oasis, a source of strength to help the immune system fight back. Further research is needed to fully understand its potential, but it's a promising step towards a healthier future for those living with HIV.

Date :
  1. Date Completed 1994-07-26
  2. Date Revised 2019-07-18
Further Info :

Pubmed ID

8011237

DOI: Digital Object Identifier

10.1097/00002030-199401000-00009

Related Literature

Article Analysis
・Side Effects of zidovudine injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.